The Grand Rapids Clinical Oncology Program (GRCOP) has achieved a national reputation for excellence in community cancer care through its 34-year participation in programs of the National Cancer Institute. The GRCOP comprises a consortium of seven health care systems/hospitals in Western and Northern Lower Michigan and seeks to continue to meet the community's need for innovative and relevant studies of promising therapeutic modalities and cancer controls research. The ongoing mission of the Grand Rapids Clinical Oncology Program is to assure that every person in the region served is provided an opportunity for participation in national cancer prevention and treatment clinical trials. Additionally, it is a major educational resource for professional and laypersons alike regarding cancer and the NCI clinical trials program. This grant application encompasses and articulates an ever-expanding vision for the GRCOP. Key strategies to increase patient access and accrual to research protocols include: (1) expansion of on-site screening and patient identification for enrollment in research protocols;(2) strengthening referral systems for symptom management trials to include physician specialists and allied health professionals;(3) maintaining a protocol menu that is comprehensive yet efficient to administer;(4) expansion of the Radiation Therapy Oncology Group (RTOG) as a research base for all component sites;(5) implementing a targeted clinical trials program for adolescents/young adults with increased protocol availability for this population. Strategic initiatives to increase access to and participation in cancer clinical trials by underserved and minority populations include alignment with community organizations;a key element in this regard will be the work of the GRCOP Patient Advisory Board. An expanding focus on the growing Hispanic/Latino population is planned. Of importance during this upcoming grant cycle will be the GRCOP's ongoing development of the GRCOP website in order to improve the efficiency and cost-effectiveness of clinical trial administration and regulatory compliance.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035178-30
Application #
8475428
Study Section
Special Emphasis Panel (ZCA1-SRLB-Y (J1))
Program Officer
Whitman, Cynthia B
Project Start
1987-06-01
Project End
2015-05-31
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
30
Fiscal Year
2013
Total Cost
$1,417,905
Indirect Cost
$413,508
Name
Spectrum Health Hospitals
Department
Type
DUNS #
047593173
City
Grand Rapids
State
MI
Country
United States
Zip Code
49503
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Kernstine, Kemp H; Moon, James; Kraut, Michael J et al. (2014) Trimodality therapy for superior sulcus non-small cell lung cancer: Southwest Oncology Group-Intergroup Trial S0220. Ann Thorac Surg 98:402-10
Erba, Harry P; Othus, Megan; Walter, Roland B et al. (2014) Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. Leuk Res 38:329-33
Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8
Bepler, Gerold; Zinner, Ralph G; Moon, James et al. (2014) A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer 120:2343-51
Allen, Jeffrey W; Moon, James; Redman, Mary et al. (2014) Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol 32:2463-70
Philip, Philip A; Goldman, Bryan; Ramanathan, Ramesh K et al. (2014) Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWO Cancer 120:2980-5
Goldkorn, Amir; Ely, Benjamin; Quinn, David I et al. (2014) Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 32:1136-42
Carson 3rd, William E; Unger, Joseph M; Sosman, Jeffrey A et al. (2014) Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res 2:981-7
Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8

Showing the most recent 10 out of 150 publications